Loading...
XIDX
KLBF
Market cap3.17bUSD
Nov 12, Last price  
1,265.00IDR
Name

Kalbe Farma Tbk PT

Chart & Performance

D1W1MN
XIDX:KLBF chart
P/E
15.62
P/S
1.62
EPS
81.00
Div Yield, %
2.45%
Shrs. gr., 5y
-0.58%
Rev. gr., 5y
8.85%
Revenues
35.32t
+8.27%
6,071,550,437,9677,004,909,851,9087,877,366,385,6339,087,347,669,80410,226,789,206,22310,911,860,141,52313,636,405,178,95716,002,131,057,04817,368,532,547,55817,887,464,223,32119,374,230,957,50520,182,120,166,61621,074,306,186,02722,633,476,361,03823,112,654,991,22426,261,194,512,31328,933,502,646,71930,449,134,077,61832,627,776,108,00035,324,544,000,000
Net income
3.66t
+13.10%
764,357,450,660811,647,239,876825,504,633,3481,049,667,116,5481,343,798,968,4221,522,956,820,2921,733,928,105,6031,919,508,370,3122,064,686,665,4422,004,236,980,1272,299,734,572,5502,403,605,933,3992,457,129,032,2712,506,764,572,0752,733,259,864,5963,183,621,310,0433,382,209,769,0152,766,748,040,0553,240,636,626,0003,664,998,000,000
CFO
3.27t
-31.65%
640,610,354,353362,898,238,846807,700,535,3441,363,583,440,6011,153,591,787,8711,473,495,223,3061,376,343,990,025927,163,654,2122,316,125,821,0452,456,995,428,1062,159,833,281,1762,008,316,536,0662,770,775,949,4592,502,968,822,3914,214,744,628,5202,825,946,276,0863,769,449,698,8122,907,475,171,0104,785,179,041,0003,270,655,000,000
Dividend
Jun 04, 202536 IDR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Indonesia-based pharmaceutical powerhouse, PT Kalbe Farma Tbk., along with its affiliated companies, is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products throughout the country. The organization structures its operations across four primary business units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers a diverse range of medications, including generic, branded, and licensed drugs such as Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG, which are supplied to hospitals, pharmacies, and drug retailers. Beyond prescription items, its product line includes over-the-counter medicines, energy drinks, ready-to-consume beverages, dietary supplements, and other preventive health products. Furthermore, the company provides specialized nutritional offerings catering to all age groups—from infants and toddlers to children, adolescents, adults, expectant and lactating mothers, and seniors—as well as individuals with particular medical dietary requirements. The firm also extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence studies, and analytical services. Its activities further include the provision of animal health products and the operation of the Mitrasana Clinics healthcare service network. Additionally, PT Kalbe Farma Tbk. offers health screening services, acts as an agent and representative for biotechnology products, distributes various consumer goods, medical equipment, cosmetics, and other trade items. It also trades in medical and laboratory apparatus and supplies, raw materials for pharmaceutical production, and consumable products essential for hemodialysis therapy, while also providing advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.
IPO date
Jul 30, 1991
Employees
13,165
Domiciled in
ID
Incorporated in
ID

Valuation

Title
IDR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT